NCCN Guidelines for Patients® | Lung Cancer - Non-Small Cell Lung Cancer

53 NCCN Guidelines for Patients ® : Lung Cancer – Non-Small Cell, 2018 5 Overview of cancer treatments Targeted therapy Dabrafenib and trametinib are made as pills. Both should be taken on an empty stomach. Dabrafenib is taken twice a day. Trametinib is taken once a day at the same time each day. Common side effects of dabrafenib with trametinib include fever, chills, and fatigue. You may feel nauseated, vomit, have diarrhea, or not feel hungry. Your skin may become dry or get a rash. You face, arms, or legs may swell. Bleeding, cough, and shortness of breath are also common. There are rare but serious side effects. These include tears in your gut, blood clots, and heart, eye, or lung problems. Fever, rash, or bleeding may be severe. Blood sugar may become very high. Other types of cancer may develop. If you want to have a baby, tell your doctor. Sperm counts can drop in men. Women may have trouble getting pregnant. Don’t use dabrafenib and trametinib if you’re pregnant or breastfeeding. These medicines may harm your baby. Dabrafenib only Dabrafenib and trametinib may be too hard on your body. In this case, dabrafenib used alone may be an option. Common side effects include changes in your skin. Your skin may become thick or get warts. Your hands or feet may become red, swell, peel, or feel tender. Other common side effects are fever, joint aches, and hair loss. Vemurafenib Vemurafenib may also be an option if dabrafenib with trametinib can’t be taken. It works like dabrafenib and stops BRAF signals. It is used to treat melanoma. More research is needed on lung cancer. Vemurafenib is made as a pill. It is taken twice a day. It can be taken with or without food. Side effects may be alike for melanoma and lung cancer. Common side effects for melanoma treatment include joint pain, tiredness, and nausea. Your skin may get a rash or warts. You may have hair loss or easily get a sunburn. You may feel itchy. Figure 18 BRAF and MEK targets Some lung cancers have overactive BRAF proteins. These proteins send too many growth signals. Targeted therapy stops the signal from BRAF or the next protein (MEK) in the signal pathway. Copyright © 2017 National Comprehensive Cancer Network ® (NCCN ® ). Signal pathway in cancer cell trametinib P dabrafenib vemurafenib P BRAF MEK